Although we validated key hits in patient-derived xenograft (PDX) models of breast and multiple breast cancer cell lines, the generalizability of these findings across all PLK1-driven cancers remains to be further tested in a broader panel of tumor types. This evidence concerns the gene PLK1 and breast cancer.